A Look at Regeneron Pharmaceuticals’s (REGN) Valuation Following Recent Share Price Gains

Regeneron Pharmaceuticals (REGN) shares have been actively watched by investors recently, following solid revenue and net income growth over the past year. The stock has delivered a 20% return in the past month and nearly 19% over the past 3 months.

See our latest analysis for Regeneron Pharmaceuticals.

After an impressive run over the past month, Regeneron Pharmaceuticals’ share price has rebounded and recouped much of its ground lost earlier this year. Although the one-year total shareholder return stands at -7.97%, the recent momentum suggests that investor sentiment toward the stock may be shifting, as REGN posts one of the strongest 30-day share price returns in the sector.

If Regeneron’s resurgence has you thinking about other healthcare opportunities, now is a great time to explore the full universe with our See the full list for free.

With REGN showing robust recent gains but still trailing its one-year peak, the key question now is whether the market is undervaluing the company’s long-term potential or if future growth is already fully reflected in the price.

Most Popular Narrative: 7.9% Undervalued

With Regeneron Pharmaceuticals closing at $693.50 and the most widely followed narrative setting fair value at $753.17, the narrative suggests there is still meaningful upside. It also lays out an earnings and pipeline case few investors anticipate.

Regeneron's broad and advancing pipeline, including recent or upcoming pivotal data in immunology, oncology (notably Lynozyfic and odronextamab), genetic medicines, and obesity, positions the company to benefit from demographic-driven increases in demand for advanced therapies and from the rise in personalized and precision medicine. This supports future revenue growth and pipeline-driven earnings upside.

Read the complete narrative.

Curious about which bold projections and pipeline milestones justify this premium? The narrative hinges on aggressive expansion in new markets, operational breakthroughs, and financial assumptions that could surprise even seasoned analysts. Find out what makes this fair value so compelling or controversial.

Result: Fair Value of $753.17 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, persistent regulatory delays and pressure on Eylea’s market share could still challenge the optimistic outlook for Regeneron’s growth story.

Find out about the key risks to this Regeneron Pharmaceuticals narrative.

Build Your Own Regeneron Pharmaceuticals Narrative

If you see the story differently or want to investigate the numbers for yourself, you can build your own narrative in just a few minutes, and Do it your way

A good starting point is our analysis highlighting 3 key rewards investors are optimistic about regarding Regeneron Pharmaceuticals.

Looking for more investment ideas?

Unlock your investing edge by tapping into new trends, untapped value, and high-potential companies before others spot them. Stay ahead and do not let these opportunities pass you by.

• Boost your long-term income and stability with these 16 dividend stocks with yields > 3% which offers yields over 3% for dependable cash flow.
• Tap into the fast-growing sector of artificial intelligence with these 25 AI penny stocks, which is reshaping industries and transforming the way the world works.
• Catch undervalued stock opportunities right now with these 879 undervalued stocks based on cash flows to find real bargains based on future cash flows.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com